申请人:THERAVANCE BIOPHARMA R&D IP, LLC
公开号:US10392368B2
公开(公告)日:2019-08-27
The invention provides compounds of formula (I):
or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.
本发明提供了式 (I) 的化合物:
或其药学上可接受的盐,其中变量在说明书中定义,是 JAK 激酶,特别是 JAK3 的抑制剂。本发明还提供了结晶形式、包含此类化合物的药物组合物、使用此类化合物治疗胃肠道疾病和其他炎症性疾病的方法,以及制备此类化合物的有用工艺和中间体。